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Abstract
Background
There is a scarcity of data on the distribution of human papillomavirus (HPV) genotypes in
the HIV positive population and in invasive cervical cancer (ICC) in Kenya. This may be dif-
ferent from genotypes found in abnormal cytology. Yet, with the advent of preventive HPV
vaccines that target HPV 16 and 18, and the nonavalent vaccine targeting 90% of all ICC
cases, such HPV genotype distribution data are indispensable for predicting the impact of
vaccination and HPV screening on prevention. Even with a successful vaccination pro-
gram, vaccinated women will still require screening to detect those who will develop ICC
from other High risk (HR) HPV genotypes not prevented by current vaccines. The aim of
this review is to report on the prevalence of pHR/HR HPV types and multiple pHR/HR HPV
genotypes in Kenya among HIV positive women with normal, abnormal cytology and ICC.
Methods
PUBMED, EMBASE, SCOPUS, and PROQUEST were searched for articles on HPV infec-
tion up to August 2nd 2016. Search terms were HIV, HPV, Cervical Cancer, Incidence or
Prevalence, and Kenya.
Results
The 13 studies included yielded a total of 2116 HIV-infected women, of which 89 had ICC.
The overall prevalence of pHR/HR HPV genotypes among HIV-infected women was 64%
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(95%CI: 50%-77%). There was a borderline significant difference in the prevalence of pHR/
HR HPV genotypes between Female Sex workers (FSW) compared to non-FSW in women
with both normal and abnormal cytology. Multiple pHR/HR HPV genotypes were highly
prominent in both normal cytology/HSIL and ICC. The most prevalent HR HPV genotypes
in women with abnormal cytology were HPV 16 with 26%, (95%CI: 23.0%-30.0%) followed
by HPV 35 and 52, with 21% (95%CI: 18%-25%) and 18% (95%CI: 15%-21%), respec-
tively. In women with ICC, the most prevalent HPV genotypes were HPV 16 (37%; 95%CI:
28%-47%) and HPV 18 (24%; 95%CI: 16%-33%).
Conclusion
HPV 16/18 gains prominence as the severity of cervical disease increases, with HPV 16/18
accounting for 61% (95%CI: 50.0%-70.0%) of all ICC cases. A secondary prevention pro-
gram will be necessary as this population harbors multiple pHR/HR HPV co-infections,
which may not be covered by current vaccines. A triage based on FSW as an indicator may
be warranted.
Background
Human papillomavirus (HPV) is a sexually transmitted infection, and high-risk (HR) HPV
DNA has been shown to be present in 99.7% of cervical cancers worldwide [1]. Over 200 HPV
genotypes have been identified and are divided into high-risk (HR) and low-risk (LR) carcino-
gens depending on their potential to cause cancer. HR types include 16, 18, 31, 33, 35, 39, 45,
51, 52, 56, 58, 68 and 59. Others are classified as potential High risk (pHR) (types 53, 66, 70, 73,
82). HPV 16 and HPV 18 are the most virulent HR-HPV genotypes, causing about 70% of all
invasive cervical cancer (ICC) in the world [2].
Apart from a higher prevalence and broader range of HR HPV, HIV immunosuppression
has been linked to multiple HPV infections [1, 3–5]. The inability to clear HPV infections and
the reactivation of latent HPV infections, a result of immune suppression, have been attributed
to multiple HPV genotype co-infections [6, 7].
Moreover, HIV positive women are more at risk for progression to cervical intraepithelial
neoplasia grade 3 (CIN3). In 2007, the World Health Organisation (WHO) included ICC to
the stage “4” of the AIDS classification of its clinical staging and case definition of HIV for
resource-constrained settings [8].
Several countries, including Kenya, have licensed and adopted the bivalent HPV vaccine
(Cervarix™) that protects against HPV genotypes 16 and 18 and the quadrivalent vaccine (Gar-
dasil™) that protects against HPV genotypes 6, 11, 16 and 18 [9]. However, HPV vaccine uptake
has been limited, with a recent longitudinal study in Eldoret, Kenya, reporting that only 31%
(79/254) of those who entered the follow-up study to have been vaccinated [10].
In 2014, a nonavalent vaccine, not yet commercialized in Kenya, containing additional HPV
types 6, 11, 16, 18, 31, 33, 45, 52, and 58 antigens will have direct implications for cervical can-
cer incidence and prevention in all regions of the world with the potential to prevent almost
90% of ICC cases worldwide.
Whilst the immunogenicity of both the bivalent and quadrivalent vaccines has also been
recently documented in HIV positive women, the effectiveness of these vaccines in curbing the
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incidence of ICC is contingent upon the prevalence of oncogenic vaccine genotypes in HIV
positive women [11, 12].
Considering the very high incidence of HIV and ICC observed in sub-Saharan Africa, the
HPV type distribution is still not well characterised among HIV-infected populations in the
region [13]. Whilst in some European populations a positive association of HIV infection and
ICC has been reported, the picture lacks clarity in Africa [14–16]. Additionally, with the estab-
lishment of HAART programmes and consequent increase in life expectancy in HIV-positive
women, a change in the pattern of the burden of HIV-related cancers can be expected for these
patients.
Preceded only by breast cancer, ICC is the secondmost prevalent cancer among women in
Kenya, and its incidence is increasing [17]. Despite high ICC prevalence, cervical screening
uptake is low, with a 2014 cross sectional study in the Kisumu East District of Nyanza Province
reporting a 17.5% screening uptake [18]. A successful vaccination program will not obviate the
need for women to undergo screening to detect other oncogenic HPV genotypes. TheWHO
now recommends that “once a woman has been screened negative, she should not be rescreened
for at least 5 years, but should be rescreenedwithin ten” [19]. However, there is current scant
evidence to support the adequateness of this guideline in HIV-infected women.
Given the scarcity of resources, screening programs will need to be tailored to the human
and financial resources of the region, and a triage for HPV screening among vulnerable women
envisaged. In Kenya, as in many parts of sub-Saharan Africa, female sexual workers (FSW)
bear the greatest burden of HIV infection, and as early as 1985, a study reported that HIV prev-
alence was as high as 61% among a group of FSW in Nairobi [20]. A recent study estimated
that 5 percent of the urban female population of reproductive age could be sex workers, making
this population particularly at risk for HIV-HPV co-infection. Some published studies have
suggested differential prevalence of pHR/HRHPV infection among FSW, however there are
no pooled estimates for this population [21–23].
The overarching aim of this review is to guide primary and secondary prevention of cervical
cancer programs in Kenya and has as objectives: 1) determine the prevalence of pHR/HRHPV
genotypes among HIV-infected women with normal cytology to ICC; 2) explore the differential
prevalence of pHR/HRHPV infections among FSW and non FSWwomen; 3) establish the
pooled estimates for different pHR/HRHPV genotypes in these populations; 4) determine the
pHR/HRHPV genotypes and multiple HPV genotypes in Kenya among HIV positive women
with normal cytology/abnormal cytology to ICC.
Method
Search Strategy and Selection Criteria
The search strategy was designed by a medical librarian to identify studies reportingHPV
genotypes associated with normal, abnormal cytology and cervical cancer in HIV infected
women living in Kenya. We conducted this systematic review and meta-analysis based on a
pre-defined search protocol that conformed to the criteria set out by the Meta-Analysis of
Observational Studies in Epidemiology (MOOSE) group and was in accordance with the
PRISMA statement [24, 25]. (S1 PRISMA Checklist)
We systematically searched PubMed, EMBASE, PROQUEST, and SCOPUS without any
language restrictions. Reference lists of all retrieved articles and previous systematic reviews
were checked for further eligible publications up to August 2nd 2016.
The domains of the search terms were HIV, HPV, cervicalCancer, incidence or prevalence,
and Kenya. We combined HPV and cervical cancer with the Boolean operator “OR”, and the
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result was combined with the other terms with “AND”. Full search strategy for the databases is
given in S1 Search Strategy.
Studies were eligible if they reported our main outcomes of interest, overall pHR/HRHPV
frequency as well as specific pHR/HRHPV genotype frequency in both a general HIV study
population or in HIV infected FSW study population. If the HPV prevalence was not disaggre-
gated into pHR/HRHPV genotypes, or no frequency of pHR/HRHPV genotype, multiple
pHR/HRHPV genotypes or/and no disaggregated frequency of pHR/HRHPV genotype pro-
vided for Kenya, the authors of the retrieved articles were contacted. Another inclusion crite-
rion was that HPV testing had to be performed through validated and commercial or WHO
CE labelled PCR testing. Studies were included if their design was a cohort, cross-sectional,
case-control or case-case study. Potential duplicate data were searched for.
We excluded studies conducted on males, studies that did not provide pHR/HRHPV infec-
tion data by HIV status or if it was not possible to calculate the above information from data
given (Fig 1).
Fig 1. Flow diagram.
doi:10.1371/journal.pone.0163965.g001
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For the first research question, data were extracted on the total number of HIV infected peo-
ple with any pHR/HRHPV genotype. The prevalence among HIV infected women was calcu-
lated using the total number of women with pHR/HRHPV genotypes divided by the total
number of HIV-infected women.We did not disaggregate by cytological status as we were
interested in obtaining a general picture of the burden among HIV-infected women in Kenya,
which would include women with ICC.
For the second research question, the pooled prevalence of pHR/HRHPV genotypes was
compared between FSW and non FSW. As no cases of ICC have been observed among FSWs
and ICC cases having a very high pHR/HRHPV genotype, the denominator included only
HIV infected women with normal and abnormal cytology.
For the third research question, due to the small number of studies and study population,
the frequency of pHR/HRHPV genotypes were only broken down into three groups: normal,
abnormal cytology and ICC. Indeterminate cytological results were excluded, and inflamma-
tion was categorized as normal cytology.
For the fourth research question, the number of multiple infection pHR/HRHPV geno-
types in HIV-infected women with normal to abnormal cytologywas compared to the num-
ber of multiple infections in women with ICC. Their respective population was used as a
denominator.
Subgroup analyses
A sub-analysis was performed to assess differential prevalences during the total time of sample
collection 1994–2008, by categorizing observations as pre-2004 or 2004–2008. This dichotomi-
zation was chosen to reflect changes in PCR sensitivities, changes of screening protocols, and
the 2003 review of the epidemiological classification of oncogenic HPV genotypes [2].
Data Abstraction
All studies were independently reviewed and critically evaluated for inclusion by two authors
(SM andWA). All data was extracted independently and in duplicate manner by two investiga-
tors (SM andWA). The following items were recorded: first author, study period, publication
year, study type, type of sampling, sample collectionmethod, study population, total sample
size, HIV and pHR/HRHPV prevalence of infected women, mean and standard deviation
/median age with IQR number of women with specific pHR/HRHPV types if available, nor-
mal/abnormal cytology, invasive cervical cancer (ICC), HPV detectionmethod, and data on
FSW.
Statistical Analysis
The HPV prevalence, type specific prevalence, 95% CI of prevalence of HPV infection, and spe-
cific HPV genotype were calculated according to Wald method.We used the DerSimonian and
Laird random-effectsmodel to pool overall HPV prevalence, as we expected the level of hetero-
geneity to be significant. The Q test was used to assess the presence of heterogeneity and the I2
index to quantify the extent of heterogeneity; p<0.10 was considered indicative of significant
heterogeneity. To assess the robustness of pHR/HRHPV prevalence in HIV infected women,
we performed a leave-one-out sensitivity analysis by iteratively removing one study at a time
while recalculating the co-infection prevalence rate. Forest plots were produced to show the
pooled estimate of the distribution of genotypes. Analysis was undertaken using STATA ver-
sion 13 (Corporation, College Station, TX, USA). The STATA commandMetaprop was used
as it provides appropriate methods for dealing with proportions close to 0 [26].
HPV Genotypes among HIV Positive Women in Kenya
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Ethical approval
No ethical approval was required as this was a meta-analysis (analysis of secondary data).
Results
Search results and study characteristics
OnAugust 2nd, 2016, we retrieved 771 studies from PUBMED, EMBASE, SCOPUS, and PRO-
QUEST of which 310 were duplicates. We title/abstract-screened461 articles, of which 29 studies
were eligible for full text screening. Finally, 13 studies were included for this review (Fig 2). For
pooling the pHR/HRHPV prevalence, all 13 studies reported this prevalence and hence were eli-
gible. For pooling the different pHR/HRHPV genotypes, only 10 studies provided data on differ-
ent HPV genotypes. Of these 10 studies, one could not be used due to lack of disaggregated
pHR/HRHPV genotype data. Another study did not break down the HPV genotypes according
to cytological results, and another study did not provide geographically disaggregated data, and
so were also excluded from our analysis.
From the 7 eligible studies, 5 studies reported on pHR/HRHPV genotypes in HIV infected
women with normal cytology and 6 reported on abnormal cytology. Three studies reported on
frequency of pHR/HRHPV genotypes in HIV infected women with ICC.
From the 13 eligible studies, data on multiple pHR/HRHPV genotypes were only reported
in 7 studies. Data were broken into two groups, normal/abnormal cytology versus ICC to juxta-
pose the difference in multiple pHR/HRHPV genotypes prevalence.
The 13 studies included in this meta-analysis yielded a total number of 2116 HIV positive
women with individual sample sizes ranging from 46 to 498 (median = 74 women). Eleven
studies were based on clinic-based recruitment in Kenya, (Rahman et al 2011 [27], Yamada
et al 2008 [28], Vuyst et al 2003 [29] & 2012a [30] & 2012b [31], Temmerman et al 1999 [32]
Vuyst et al 2008 [33] and Menon et al 2016) [34]; (Chung et al 2013 [35], Maranga et al 2013
[36], Luque et al 2010 [37]); one study used peer leader recruitment (Patel et al 2010) [38], and
another used snowball sampling of FSW (Luchters et al 2010) [39]. Different protocols and
techniques were used to determineHPV infection throughout Kenya. (Fig 2).
Meta-analysis results
Among the total 2116 HIV positive women, 1244 women were diagnosedwith pHR/HRHPV
infections. Pooled prevalence of pHR/ HRHPV genotypes among HIV infected women was
64% (95%CI: 50%-77%) and displayed significant heterogeneity, I2 = 98.1%, p<0.000. Pooled
HPV prevalence was not substantially sensitive to the exclusion of any single study test (Fig 3).
There was a borderline statistically significant pooledHRHPV prevalence among FSW.
Pooled HR HPV prevalence among FSWwas 75% (95%CI: 70%-79%) compared to 57% (95%
CI: 45%-70%) among non FSWs (Fig 4).
Both HIV infected women with normal cytology to HSIL and ICC had a high prevalence of
multiple pHR HPV genotypes, 42% (95%CI: 35%; 49%) versus 35% (95%CI: 25%; 45%) (Fig 5).
Out of the total number of HIV-positive women, the most prevalent HR HPV genotypes in
women with normal cytologywere HPV 52 with a pooled estimate of 26% (95%CI: 21%-30%-
38.4; n = 92), followed by HPV 35, 20% (95%CI: 16% - 25%; n = 72). The most prevalent
pHR/HRHPV genotypes in women with abnormal cytologywere HPV 16 with 26%, (95%CI:
23%-30%; n = 156), followed by HPV 35 and 52, with 21% (95%CI: 18%-25%; n = 126) and
18% (95%CI: 15%-21%; n = 108), respectively (Fig 6).
In HIV infected women with ICC, the most prevalent HR HPV genotype in women were
HPV 16 (pooled prevalence 37%; 95%CI: 28% - 47%; n = 33), followed by HPV18 (24%; 95%
HPV Genotypes among HIV Positive Women in Kenya
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Fig 2. Studies included in the meta-analysis CB: Cervical brush; FB: Frozen biopsy; CSC: Cervical
Scraped cell.
doi:10.1371/journal.pone.0163965.g002
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CI: 16%-33%; n = 21), followed by a 15% prevalence of HPV 58 (95%CI: 9%-23%; n = 11).
HPV 31, 33, 35, 53 and 56 were also detected (Fig 6).
In our subgroup analysis, time period did not appear to impact the pHR/HRHPV preva-
lence, with pooled estimates overlapping, pre 2004 65% (95%CI: 44%-88%) and post 2004, 64%
(95%CI: 50%-77%) (Fig 7).
Discussion
Ourmeta-analysis demonstrated a high burden of HR-HPV genotypes in a general HIV popu-
lation, significantly higher than the recent meta-analysis on pooledHPV prevalence in the gen-
eral female population in eastern Africa (42.2%) [40].
Prevalence of specific PHR/ HR HPV genotypes in HIV-infected women
with abnormal cytology
It was also found that, whilst HPV 52, followed by HPV 35, 53 and 56 were the most prevalent
pHR/HRHPV genotypes detected in HIV positive women with normal cytology, in women
Fig 3. Pooled pHR /HR HPV prevalence among HIV-positive women.
doi:10.1371/journal.pone.0163965.g003
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with abnormal cytology, HPV 16 shifted to first place and was followed by HPV 35 and 52.
Nevertheless, in women with ICC, HPV 18 gained prominence, ranking second after HPV 16.
Data on HPV type distribution in invasive and pre-invasive cervical cancer is required to
predict the future impact of HPV16/18 vaccines, the future nonavalent vaccine and HPV-
based screening test. Our systematic review suggests that HPV 16 regains it prominence in
HIV women with abnormal cytology, though this difference was not statistically significant.
Our high pooled estimates suggest a prominent place for non 16/18 HPV types, including
HPV 35, 52, 56, 58, 53, and 31 in HIV infected women with abnormal cytology. Similar obser-
vations have also beenmade from previous studies carried out in Africa and in the world
where detection of non-16/18 HPV type patterns in HIV infected individuals is commonplace
[41] [42].
Fig 4. pHR/HR HPV prevalence in FSW versus non FSW.
doi:10.1371/journal.pone.0163965.g004
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Our pooled estimates are also in line with those of a 2015 meta-analysis on the general
female population with LSIL from sub Saharan Africa for which HPV 16, 35, 52, 18, 53, 56, 58,
51, 45 and 66 were the top ten most common genotypes. Albeit, we do not have pooled esti-
mates for HSIL, the ranking of HPV 16, followed by HPV 35 and 52 observed in our study is in
line with that observed in eastern and southern regions of Africa where HPV 16 was estimated
at 28%, followed by HPV 52 (16.5%) and HPV 35 (15.1%).
The relatively high pooled prevalence of HPV 53 in our meta-analysis suggests that HPV 53
plays a more prominent role in HIV infected women. Our pooled estimate in abnormal cytol-
ogy of 12% is about twice as high as the pooled estimate found in Eastern African women
(LSIL: 7.1% and HSIL: 5.9%), as well as the pooled 6.8% estimate in HIV infected women with
LSIL and the 2.1% estimate observed in women with HSIL by Clifford et al (2006) [43].
Fig 5. Prevalence of multiple pHR/HR HPV infection among HIV positive women, separated for women with normal cytology
to HSIL and for women with ICC.
doi:10.1371/journal.pone.0163965.g005
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Fig 6. Pooled estimates of genotype specific pHR/HR HPV prevalence, separated for women with
normal/abnormal cytology and women with ICC.
doi:10.1371/journal.pone.0163965.g006
HPV Genotypes among HIV Positive Women in Kenya
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Prevalence of specific PHR/ HR HPV genotypes in HIV-infected women
with ICC
The preponderance of both HPV 16 and HPV 18 in ICC cases in our meta-analysis is in agree-
ment with the findings of the systematic review undertaken in Uganda and with the recent
meta-analysis of HPV prevalence in women with normal cervical cytology to neoplasia in
Africa [3, 40]. However, our pooledHPV 16/18 estimate of 61% (95%CI: 50.0%-70.0%) is
lower than the 75.4% observed in Eastern African women with ICC.
Compared to the pooled estimates of 4.1% reported in the meta-analysis of HPV prevalence
in eastern Africanwomen with ICC, we found a HPV 52 prevalence of 11% (95%CI 6.0%-19.0%)
Fig 7. pHR/HR HPV prevalence among HIV-positive women stratified by pre 2004 and post 2004 time period. This forest plot
reports the prevalence of pHR/HR HPV in HIV-infected women with normal cytology to ICC according to pre 2004 to after 2004.
doi:10.1371/journal.pone.0163965.g007
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which was also present in single-type infections,However, our study found a similar prevalence
of HPV 45, 11% (95%CI:6.0%-19.0%) compared to 9.1%.
In this review, we found that the prevalence of multiple HR HPV co-infectionswas analo-
gous in women with normal cytology/HSIL to that of women with ICC, which may suggest
that a synergistic interaction between pHR/HRHPV genotypes remains high in HIV women.
In our analysis comparing FSWwho are at higher risk for STIs, our meta-analysis suggested
that the prevalence of having pHR/HRHPV genotypes in FSWwas statistically significantly
higher than in non FSW. However, our subgroup analysis of pre-2004 compared to post 2004,
revealed no statistically significant differences in pooled pHR/HRHPV prevalence.
Strengths and limitations
To our knowledge, this systematic review represents the first attempt to evaluate the prevalence
of HPV infections in HIV infected women, prevalence of different HR HPV genotypes in HIV
infected women with normal, abnormal cytology and ICC in Kenya, and the second one on the
sub Saharan continent attempting to measure the burden of HPV infection and ICC [44].
Another strength of this study is that it includes studies from different settings, including a
family planning clinic, HIV clinics, and a community-based setting, which enabled us to cap-
ture a more representative HIV positive female population in Kenya. In addition to the diver-
sity of settings and median age of the study population, the catchment of clinics may have
differed in terms of socioeconomic status, which as a corollary, may have had an impact on the
levels of immunosuppression.
The data should be interpreted in light of a number of limitations, including the small num-
ber of studies examining genotypes specifically in HIV infected women, especially with ICC as
an endpoint. Our sub analysis did not reveal any statistically significant differences between
pre 2004 and post 2004 suggesting that heterogeneity may not have significantly caused by an
increase of PCR sensitivity, a wider range of pHR/ HRHPV genotypes testing over time, and a
review of classification of HPV genotypes. However, of consideration is that some of the tests
described are performed at analytical sensitivity while others have been validated clinically and
use a clinical threshold, rendering a high variability of PCR outcome.
Another cause of heterogeneity may be that HIV-infected women with low CD4 counts are
at risk for reactivation of HPV. However, a meta regression for age, CD4 cell count, HIV viral
load or antiretroviral treatment could not be performed, as no individual information was
available for these clinical parameters, which would allow adjustment or stratification of type-
specificHPV prevalence for these variables. The high heterogeneity may be attributed to the
different settings from which the study population was derived, including family planning
facilities, HIV clinics and community-based settings. The high I2 that we encountered is in line
with that observed in the 2015 meta-analysis from sub-Saharan Africa, where heterogeneity
was found to be substantial, ranging from ICC: I2 = 88.8% to 99.1% in women with normal
cytology [40]
In addition, another limitation relates to the cross-sectional analysis of studies with cross
sectional study designs as well as baseline data on HPV and HIV derived from cohort studies.
The temporal criterion of causality is not fulfilled, therefore reversal causality cannot be
excluded.
Potential reduction of ICC following an effective vaccine
Given that very few studies looked at type distribution in ICC in HIV positive women in
Kenya, it is difficult to estimate the potential effectiveness of the bivalent or nonavalent vac-
cines. The still poorly characterised association betweenHIV and ICC causes a public health
HPV Genotypes among HIV Positive Women in Kenya
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concern in Kenya, which currently has 1.6 million HIV-positive women whomay well have an
increased risk of developing ICC [45].
Data from the present meta-analysis indicate that current HPV 16/18 genotypes can be
found in 61% of women with ICC. However, pooled estimates suggest that a 90% reduction of
cervical cancer afforded by the nonavalent vaccinemay be attained.
Whether Gardasil and Cervarix can attain a 70% reduction of cervical cancer may be contin-
gent upon the natural history of the imputed pHR/HPV genotype in cancer genesis. However,
with the high presence of other pHR/HRHPV genotypes in HIV infected women with ICC in
Kenya, it is currently not possible to attribute a direct association between a specific genotype
in cancer genesis as its relevance may be inflated.
In order to assess the potential reduction of ICC cases by 70%, an important research gap to
address is the vaccines’ cross protection against HPV 45. Studies have shown that both current
vaccines Gardasil and Cervarix afford cross protection against type 45, with Cervarix offering a
higher degree of effectiveness [46]. However, this cross protection still has to be determined in
HIV infected women.
Apart from limited information on cross protection, it should be established whether any
concurrent HPV types may augment or decrease the efficacy of HPV vaccines, as a result of
competition among the non-vaccinated HPV types [47]. These caveats and the pooled preva-
lence of above 90% of all the genotypes incorporated in the nonavalent vaccine outline the ben-
efits of the nonavalent vaccine within this population.
Secondary prevention
Secondaryprevention, using cancer prevention tools such as visual inspectionwith acetic acid
and/or Lugol’s iodine, or detection of high risk HPV genotypes will remain indispensable for
various reasons, including the necessity of early identification of patients infected with HR/
HPV genotypes not covered by current vaccines, as well as for post bivalent, quadrivalent and
nonavalent vaccine surveillance and for unvaccinated young and older women. It is notewor-
thy that the impact of HPV vaccination will not be observed for years, especially with respect
to types associated with pre-invasive and invasive cancers, as those tend to occur in older
women.
Previous studies have shown a lack of association betweenHPV 16 and immunosuppression
[7]. Hence, despite immune reconstitution, a pooled estimate of 26%, of older HIV infected
women with abnormal cytology infected with HPV 16 or 37% of women with ICC in Kenya
may still need to be monitored regularly. Althoughmost HPV infectionsmay resolve without
treatment, the immuno-epidemiologyof some genotypes is still poorly characterized, especially
in regards to resolution of infections and regression of non-HPV 16 infections.
Because of the potential to alter their behavior in the post vaccine area and so resulting in
case type replacement, the relatively high prevalence of HPV 53 and other undiagnosedpHR/
HRHPV genotypes not covered by the nonavalent vaccine underscores the need for it to be
considered in a screening protocol. This is hampered by the lack of affordable nucleoacid
amplification methods, such as Papillomacheck, which requires specific apparatus [48, 49].
Conclusion
Our pooled estimates of HPV 16 and 18 of 61% in HIV-infected women with ICC suggest the
need for a wider protection that the nonavalent vaccine would confer.
Whilst HPV 52 is most prominent in HIV-infected women with normal cytology, in
women with abnormal cytology, HPV 16 regains its preponderance and is followed by HPV
35, only to be replaced by HPV 18 in women with ICC.
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To assess the potential vaccine efficacy in Kenya, the synergistic interactions between the
multiple genotypes harboured by HIV positive women with premalignant and malignant dis-
eases in the post vaccine era need to be elucidated.
Borderline statistically significant differences between pooled estimates of HR HPV geno-
types in FSW and non FSW suggest that cervical cancer prevention may warrant a triage based
on this indicator. An effective secondary prevention programme in HAART era, will require
that the immuno- epidemiology of specificHPV types in HIV-infected women be explored.
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